retatrutide mechanism triple agonist glp-1 gip glucagon receptor Demonstrated metabolic effects of GIP, and GCG agonism as mono, Retatrutide: The triple agonist powering

The loss of GLP-1 effect on stimulating insulin secretion at basal plasma glucose concentrations limits the hypoglycemic risk even at high pharmacological concentrations of GLP-1 (58)

GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice

The study found a higher risk of NAION in patients prescribed GLP-1 compared to those on non-GLP-1 RA medications

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)

That model is now being disrupted

Scientists are still researching to understand the connection between Zepbound and vision loss